Lame excuse as competition exists for all drugs current and in development. Leo made a mistake by hyping Absssi and then shutting it down. Couldn’t find a partner to take on Merck.
Interesting view - I have read your flowey views of B-Abssi and possibility of early approval without confirmatory study and how it can beat cubist deal and great advantage of single dose.